Highlights
The global PCR-based Enteric Disease Testing market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for PCR-based Enteric Disease Testing is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for PCR-based Enteric Disease Testing is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for PCR-based Enteric Disease Testing in Clostridium Difficile is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of PCR-based Enteric Disease Testing include Thermo Fisher Scientific, Vela Diagnostics, CorisBioconcept, Meridian Life Science, Bio-Rad Laboratories, Abbott (ALERE), bioMerieux SA, Trinity Biotech and DiaSorin Molecular, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for PCR-based Enteric Disease Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PCR-based Enteric Disease Testing.
The PCR-based Enteric Disease Testing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global PCR-based Enteric Disease Testing market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the PCR-based Enteric Disease Testing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Thermo Fisher Scientific
Vela Diagnostics
CorisBioconcept
Meridian Life Science
Bio-Rad Laboratories
Abbott (ALERE)
bioMerieux SA
Trinity Biotech
DiaSorin Molecular
Etta Healthcare (Ovagene Oncology)
ExcitePCR (PositiveID Corporation)
Flow Alliance
Fluid-Screen
FluimediX
Fluxergy
Focus Diagnostics (DiaSorin Molecular)
Future Horizon Scientific
Genalyte
GeneFluidics
GenSpeed Biotech
Gulf Bio Analytical
Hahn-Schickard
Helvoet
HemoCue
Danaher
IDEX Health&Science
iLine Microsystems
Inflammatix
Segment by Type
Analyzers/Instruments
Kits/Panels
Segment by Application
Clostridium Difficile
Campylobacteriosis
Cholera
E. coli Infection
H. pylori Infection
Salmonellosis
Shigellosis
Rotavirus Infection
Norovirus Infection
Parasitic Enteric Disease
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of PCR-based Enteric Disease Testing companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global PCR-based Enteric Disease Testing 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Analyzers/Instruments
1.2.3 Kits/Panels
1.3 麻豆原创 by Application
1.3.1 Global PCR-based Enteric Disease Testing 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Clostridium Difficile
1.3.3 Campylobacteriosis
1.3.4 Cholera
1.3.5 E. coli Infection
1.3.6 H. pylori Infection
1.3.7 Salmonellosis
1.3.8 Shigellosis
1.3.9 Rotavirus Infection
1.3.10 Norovirus Infection
1.3.11 Parasitic Enteric Disease
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global PCR-based Enteric Disease Testing 麻豆原创 Perspective (2018-2029)
2.2 PCR-based Enteric Disease Testing Growth Trends by Region
2.2.1 Global PCR-based Enteric Disease Testing 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 PCR-based Enteric Disease Testing Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 PCR-based Enteric Disease Testing Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 PCR-based Enteric Disease Testing 麻豆原创 Dynamics
2.3.1 PCR-based Enteric Disease Testing Industry Trends
2.3.2 PCR-based Enteric Disease Testing 麻豆原创 Drivers
2.3.3 PCR-based Enteric Disease Testing 麻豆原创 Challenges
2.3.4 PCR-based Enteric Disease Testing 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top PCR-based Enteric Disease Testing Players by Revenue
3.1.1 Global Top PCR-based Enteric Disease Testing Players by Revenue (2018-2023)
3.1.2 Global PCR-based Enteric Disease Testing Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global PCR-based Enteric Disease Testing 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by PCR-based Enteric Disease Testing Revenue
3.4 Global PCR-based Enteric Disease Testing 麻豆原创 Concentration Ratio
3.4.1 Global PCR-based Enteric Disease Testing 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by PCR-based Enteric Disease Testing Revenue in 2022
3.5 PCR-based Enteric Disease Testing Key Players Head office and Area Served
3.6 Key Players PCR-based Enteric Disease Testing Product Solution and Service
3.7 Date of Enter into PCR-based Enteric Disease Testing 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 PCR-based Enteric Disease Testing Breakdown Data by Type
4.1 Global PCR-based Enteric Disease Testing Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global PCR-based Enteric Disease Testing Forecasted 麻豆原创 Size by Type (2024-2029)
5 PCR-based Enteric Disease Testing Breakdown Data by Application
5.1 Global PCR-based Enteric Disease Testing Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global PCR-based Enteric Disease Testing Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America PCR-based Enteric Disease Testing 麻豆原创 Size (2018-2029)
6.2 North America PCR-based Enteric Disease Testing 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America PCR-based Enteric Disease Testing 麻豆原创 Size by Country (2018-2023)
6.4 North America PCR-based Enteric Disease Testing 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe PCR-based Enteric Disease Testing 麻豆原创 Size (2018-2029)
7.2 Europe PCR-based Enteric Disease Testing 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe PCR-based Enteric Disease Testing 麻豆原创 Size by Country (2018-2023)
7.4 Europe PCR-based Enteric Disease Testing 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific PCR-based Enteric Disease Testing 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific PCR-based Enteric Disease Testing 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific PCR-based Enteric Disease Testing 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific PCR-based Enteric Disease Testing 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America PCR-based Enteric Disease Testing 麻豆原创 Size (2018-2029)
9.2 Latin America PCR-based Enteric Disease Testing 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America PCR-based Enteric Disease Testing 麻豆原创 Size by Country (2018-2023)
9.4 Latin America PCR-based Enteric Disease Testing 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa PCR-based Enteric Disease Testing 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa PCR-based Enteric Disease Testing 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa PCR-based Enteric Disease Testing 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa PCR-based Enteric Disease Testing 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Company Detail
11.1.2 Thermo Fisher Scientific Business Overview
11.1.3 Thermo Fisher Scientific PCR-based Enteric Disease Testing Introduction
11.1.4 Thermo Fisher Scientific Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.1.5 Thermo Fisher Scientific Recent Development
11.2 Vela Diagnostics
11.2.1 Vela Diagnostics Company Detail
11.2.2 Vela Diagnostics Business Overview
11.2.3 Vela Diagnostics PCR-based Enteric Disease Testing Introduction
11.2.4 Vela Diagnostics Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.2.5 Vela Diagnostics Recent Development
11.3 CorisBioconcept
11.3.1 CorisBioconcept Company Detail
11.3.2 CorisBioconcept Business Overview
11.3.3 CorisBioconcept PCR-based Enteric Disease Testing Introduction
11.3.4 CorisBioconcept Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.3.5 CorisBioconcept Recent Development
11.4 Meridian Life Science
11.4.1 Meridian Life Science Company Detail
11.4.2 Meridian Life Science Business Overview
11.4.3 Meridian Life Science PCR-based Enteric Disease Testing Introduction
11.4.4 Meridian Life Science Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.4.5 Meridian Life Science Recent Development
11.5 Bio-Rad Laboratories
11.5.1 Bio-Rad Laboratories Company Detail
11.5.2 Bio-Rad Laboratories Business Overview
11.5.3 Bio-Rad Laboratories PCR-based Enteric Disease Testing Introduction
11.5.4 Bio-Rad Laboratories Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.5.5 Bio-Rad Laboratories Recent Development
11.6 Abbott (ALERE)
11.6.1 Abbott (ALERE) Company Detail
11.6.2 Abbott (ALERE) Business Overview
11.6.3 Abbott (ALERE) PCR-based Enteric Disease Testing Introduction
11.6.4 Abbott (ALERE) Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.6.5 Abbott (ALERE) Recent Development
11.7 bioMerieux SA
11.7.1 bioMerieux SA Company Detail
11.7.2 bioMerieux SA Business Overview
11.7.3 bioMerieux SA PCR-based Enteric Disease Testing Introduction
11.7.4 bioMerieux SA Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.7.5 bioMerieux SA Recent Development
11.8 Trinity Biotech
11.8.1 Trinity Biotech Company Detail
11.8.2 Trinity Biotech Business Overview
11.8.3 Trinity Biotech PCR-based Enteric Disease Testing Introduction
11.8.4 Trinity Biotech Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.8.5 Trinity Biotech Recent Development
11.9 DiaSorin Molecular
11.9.1 DiaSorin Molecular Company Detail
11.9.2 DiaSorin Molecular Business Overview
11.9.3 DiaSorin Molecular PCR-based Enteric Disease Testing Introduction
11.9.4 DiaSorin Molecular Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.9.5 DiaSorin Molecular Recent Development
11.10 Etta Healthcare (Ovagene Oncology)
11.10.1 Etta Healthcare (Ovagene Oncology) Company Detail
11.10.2 Etta Healthcare (Ovagene Oncology) Business Overview
11.10.3 Etta Healthcare (Ovagene Oncology) PCR-based Enteric Disease Testing Introduction
11.10.4 Etta Healthcare (Ovagene Oncology) Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.10.5 Etta Healthcare (Ovagene Oncology) Recent Development
11.11 ExcitePCR (PositiveID Corporation)
11.11.1 ExcitePCR (PositiveID Corporation) Company Detail
11.11.2 ExcitePCR (PositiveID Corporation) Business Overview
11.11.3 ExcitePCR (PositiveID Corporation) PCR-based Enteric Disease Testing Introduction
11.11.4 ExcitePCR (PositiveID Corporation) Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.11.5 ExcitePCR (PositiveID Corporation) Recent Development
11.12 Flow Alliance
11.12.1 Flow Alliance Company Detail
11.12.2 Flow Alliance Business Overview
11.12.3 Flow Alliance PCR-based Enteric Disease Testing Introduction
11.12.4 Flow Alliance Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.12.5 Flow Alliance Recent Development
11.13 Fluid-Screen
11.13.1 Fluid-Screen Company Detail
11.13.2 Fluid-Screen Business Overview
11.13.3 Fluid-Screen PCR-based Enteric Disease Testing Introduction
11.13.4 Fluid-Screen Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.13.5 Fluid-Screen Recent Development
11.14 FluimediX
11.14.1 FluimediX Company Detail
11.14.2 FluimediX Business Overview
11.14.3 FluimediX PCR-based Enteric Disease Testing Introduction
11.14.4 FluimediX Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.14.5 FluimediX Recent Development
11.15 Fluxergy
11.15.1 Fluxergy Company Detail
11.15.2 Fluxergy Business Overview
11.15.3 Fluxergy PCR-based Enteric Disease Testing Introduction
11.15.4 Fluxergy Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.15.5 Fluxergy Recent Development
11.16 Focus Diagnostics (DiaSorin Molecular)
11.16.1 Focus Diagnostics (DiaSorin Molecular) Company Detail
11.16.2 Focus Diagnostics (DiaSorin Molecular) Business Overview
11.16.3 Focus Diagnostics (DiaSorin Molecular) PCR-based Enteric Disease Testing Introduction
11.16.4 Focus Diagnostics (DiaSorin Molecular) Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.16.5 Focus Diagnostics (DiaSorin Molecular) Recent Development
11.17 Future Horizon Scientific
11.17.1 Future Horizon Scientific Company Detail
11.17.2 Future Horizon Scientific Business Overview
11.17.3 Future Horizon Scientific PCR-based Enteric Disease Testing Introduction
11.17.4 Future Horizon Scientific Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.17.5 Future Horizon Scientific Recent Development
11.18 Genalyte
11.18.1 Genalyte Company Detail
11.18.2 Genalyte Business Overview
11.18.3 Genalyte PCR-based Enteric Disease Testing Introduction
11.18.4 Genalyte Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.18.5 Genalyte Recent Development
11.19 GeneFluidics
11.19.1 GeneFluidics Company Detail
11.19.2 GeneFluidics Business Overview
11.19.3 GeneFluidics PCR-based Enteric Disease Testing Introduction
11.19.4 GeneFluidics Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.19.5 GeneFluidics Recent Development
11.20 GenSpeed Biotech
11.20.1 GenSpeed Biotech Company Detail
11.20.2 GenSpeed Biotech Business Overview
11.20.3 GenSpeed Biotech PCR-based Enteric Disease Testing Introduction
11.20.4 GenSpeed Biotech Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.20.5 GenSpeed Biotech Recent Development
11.21 Gulf Bio Analytical
11.21.1 Gulf Bio Analytical Company Detail
11.21.2 Gulf Bio Analytical Business Overview
11.21.3 Gulf Bio Analytical PCR-based Enteric Disease Testing Introduction
11.21.4 Gulf Bio Analytical Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.21.5 Gulf Bio Analytical Recent Development
11.22 Hahn-Schickard
11.22.1 Hahn-Schickard Company Detail
11.22.2 Hahn-Schickard Business Overview
11.22.3 Hahn-Schickard PCR-based Enteric Disease Testing Introduction
11.22.4 Hahn-Schickard Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.22.5 Hahn-Schickard Recent Development
11.23 Helvoet
11.23.1 Helvoet Company Detail
11.23.2 Helvoet Business Overview
11.23.3 Helvoet PCR-based Enteric Disease Testing Introduction
11.23.4 Helvoet Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.23.5 Helvoet Recent Development
11.24 HemoCue
11.24.1 HemoCue Company Detail
11.24.2 HemoCue Business Overview
11.24.3 HemoCue PCR-based Enteric Disease Testing Introduction
11.24.4 HemoCue Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.24.5 HemoCue Recent Development
11.25 Danaher
11.25.1 Danaher Company Detail
11.25.2 Danaher Business Overview
11.25.3 Danaher PCR-based Enteric Disease Testing Introduction
11.25.4 Danaher Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.25.5 Danaher Recent Development
11.26 IDEX Health&Science
11.26.1 IDEX Health&Science Company Detail
11.26.2 IDEX Health&Science Business Overview
11.26.3 IDEX Health&Science PCR-based Enteric Disease Testing Introduction
11.26.4 IDEX Health&Science Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.26.5 IDEX Health&Science Recent Development
11.27 iLine Microsystems
11.27.1 iLine Microsystems Company Detail
11.27.2 iLine Microsystems Business Overview
11.27.3 iLine Microsystems PCR-based Enteric Disease Testing Introduction
11.27.4 iLine Microsystems Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.27.5 iLine Microsystems Recent Development
11.28 Inflammatix
11.28.1 Inflammatix Company Detail
11.28.2 Inflammatix Business Overview
11.28.3 Inflammatix PCR-based Enteric Disease Testing Introduction
11.28.4 Inflammatix Revenue in PCR-based Enteric Disease Testing Business (2018-2023)
11.28.5 Inflammatix Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Thermo Fisher Scientific
Vela Diagnostics
CorisBioconcept
Meridian Life Science
Bio-Rad Laboratories
Abbott (ALERE)
bioMerieux SA
Trinity Biotech
DiaSorin Molecular
Etta Healthcare (Ovagene Oncology)
ExcitePCR (PositiveID Corporation)
Flow Alliance
Fluid-Screen
FluimediX
Fluxergy
Focus Diagnostics (DiaSorin Molecular)
Future Horizon Scientific
Genalyte
GeneFluidics
GenSpeed Biotech
Gulf Bio Analytical
Hahn-Schickard
Helvoet
HemoCue
Danaher
IDEX Health&Science
iLine Microsystems
Inflammatix
听
听
*If Applicable.
